Drug maker Suven Life Sciences today said it has recieved patent for two new chemical entities used in the treatment of diseases like Parkinson and schizophrenia from the Canadian Intellectual Property Office.
"We are pleased by the grant of patents to Suven for our pipeline of molecules in Central Nervous System (CNS) arena that are being developed for cognitive disorders, which has an estimated $20 billion market potential globally," Suven CEO Venkat Jasti said in a statement.
These patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts, it said.
A new chemical entity is a chemical molecule developed by a firm in early drug discovery stage, which after undergoing clinical trials could translate into a drug that could be a cure for some disease.
"Products out of these inventions may be out-licensed at various phases of clinical development," it said.